Amplification and/or overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 14–30% of all breast cancer cases, which are defined as HER2-positive breast cancer; this subtype is associated with a worse survival outcome2–4. Here, ERBB2 is linked to breast cancer.